CAMP4 Therapeutics

CAMP · NASDAQ

$3.16+$0.02 (+0.64%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $3.14

CAMP analyst rating

BuyConsensus of 7 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy7
Hold0
Underperform0
Sell0

12-month price target · 8 analysts

Average $10.20 (+222.8% upside)

Low: $6.06
Now: $3.16
High: $15.75

Upgrades and downgrades

The latest rating actions, newest first

CAMP analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Needham	Oct 15, 2026	Initiates	Buy	$8.00	47%
Oppenheimer	Oct 5, 2026	Initiates	Outperform	$15.00	22%
Chardan Capital	Sep 29, 2026	Maintains	Buy	$6.50 → $6.00	38%
Piper Sandler	Aug 14, 2026	Maintains	Overweight	$12.00 → $15.00	40%
JP Morgan	Jun 16, 2026	Upgrade	Neutral → Overweight	$5.00 → $9.00	48%
Chardan Capital	Jun 10, 2026	Initiates	Buy	$6.50	38%
Rodman & Renshaw	Apr 14, 2026	Initiates	Buy	$7.00	0%
Leerink Partners	Apr 2, 2026	Maintains	Outperform	$8.00 → $9.00	47%

The case for and against

Updated Oct 18, 2026

Bull case

Camp4 Therapeutics is attractive because CMP-002 has compelling proof-of-concept in SYNGAP1, restoring SYNGAP1 mRNA to healthy levels and showing reductions in seizures and behavioral deficits in preclinical models, supporting a disease-modifying profile. The commercial case is also strong, with modeled unadjusted worldwide peak revenue of $2.1 billion for CMP-002 in SYNGAP1, rising physician-identified unmet need, and a clear path to a Ph1/2MAD trial expected to start in 4Q26 with initial results assumed in 1H28. Fundamentally, the balance sheet looks supportive, with $86 million in cash at 2Q:26, pro forma cash of about $133 million, and funding estimated through YE:28, while the GSK partnership and broader RNA Activator platform add incremental strategic value.

Bear case

Camp4 Therapeutics is a development-stage, clinical-stage biopharmaceutical company with no revenue-generating products, making it highly dependent on external financing while its continuing cash burn and long clinical timelines increase dilution risk if debt or equity must be raised on unfavorable terms. Its lead SYNGAP1 opportunity still faces major fundamental hurdles because diagnosis rates remain low at roughly 15%-20%, symptoms often go unrecognized for years, and standard anti-seizure medications fail to address the ~85% of patients with epilepsy and persistent seizure burden. Although preclinical data suggest CMP-002 can restore SYNGAP1 protein to wild-type levels, the evidence remains early and translation into human outcomes is uncertain amid intense competition, regulatory risk, and unresolved intellectual property protection.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.